跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 7,011 条关于
“NLRC4 mutation”
全部
7,011
临床试验
5,481
药物
32
机构
4
资讯
1,494
上个月
Nippon Shinyaku Exercises Option for AB2 Bio's Tadekinig Alfa, Securing U.S. Commercialization Rights for Rare Autoinflammatory Diseases
去年
AB2 Bio and Nippon Shinyaku Strike $686M Deal for Rare Disease Drug Tadekinig Alfa
上个月
Nippon Shinyaku Exercises $30 Million U.S. Commercialization Option for AB2 Bio's Tadekinig Alfa in Ultra-Rare Pediatric Hyperinflammatory Syndrome
去年
Los Angeles Shigellosis Outbreak Caused by Mutation
去年
Targeted Therapies Reshape Treatment Strategies for Mutation-Driven Cancers
3年前
ASCO Updates Guidelines: ESR1 Mutation Testing Recommended for Advanced Breast Cancer
去年
Engineered Antibody Precisely Targets Mutant HER2 in Cancer Cells
10个月前
Rare POLE Gene Mutation Predicts Strong Immunotherapy Response in Colorectal Cancer
上个月
CAR T Cell Therapy Targets CALR Mutation Driving Rare Blood Cancers
2年前
Rare RAD51C Mutation Unlocks Immunotherapy Success in Pancreatic Cancer Patient
第 1 页,共 150 页
上一页
下一页